CLINICAL TRIAL TO EVALUATE THE PREVENTION OF EVENTS WITH ANGIOTENSINCONVERTING ENZYME INHIBITOR THERAPY
NIH GUIDE, Volume 23, Number 37, October 21, 1994
RFP AVAILABLE: NHLBI-HC-94-31
P.T. 34
Keywords:
Cardiovascular Diseases
Enzymes
Inhibitors
Clinical Trial
National Heart, Lung, and Blood Institute
The National Heart, Lung, and Blood Institute (NHLBI) is soliciting
proposals for a clinical trial center to determine whether or not the
addition of an angiotensin converting enzyme (ACE) inhibitor to
standard therapy in patients with known coronary artery disease and
preserved left ventricular function will prevent cardiovascular
mortality and reduce the risk of experiencing a myocardial
infarction. Other secondary endpoints will also be studied. A
minimum of 14,000 patients will be enrolled. The anticipated period
of performance is eight years beginning on or about August 1, 1995.
The Request for Proposal (RFP) NHLBI-HC-94-31 will be released on or
about October 17, 1994 with proposals due on December 5, 1994. One
award is anticipated from this RFP.
INQUIRIES
Requests must be in writing, cite RFP NHLBI-HC-94-31, and be
addressed to:
Ms. Peggy Mills
ECA Contract Section
National Heat, Lung, and Blood Institute
Federal Building, Room 200
7550 Wisconsin Avenue
Bethesda, MD 20892
.